Use of Curcumin and Flaxsseed in Radiation Pneumonopathy

姜黄素和亚麻籽在放射性肺炎中的应用

基本信息

项目摘要

DESCRIPTION (provided by applicant): The usefulness of thoracic radiotherapy is greatly limited by the sensitivity of the lung tissue to irradiation doses necessary to eradicate malignant cells. Clinically significant radiation lung injury, such as pneumonia- like inflammation and late stage fibrosis, occurs in up to 30% of patients irradiated for lung cancer and about 10-15% of other thoracic oncology patients. The need, however, to protect "normal" lung parenchyma from unacceptable radiation injury compromises the ability to deliver tumoricidal radiotherapy doses. Reactive oxygen species (ROS) such as those induced in large quantities by ionizing radiation are believed to contribute significantly to the pathogenesis of fibrotic lung disease. However the molecular pathways from the oxidative tissue insult to late radiation fibrosis are unclear and at this time, there is no available free radical scavenger to offer acceptable levels of pulmonary radioprotection without serious side effects. We and others have shown that antioxidant enzyme therapy alleviates radiation-induced fibrotic lung disease. The recently discovered NF-E2-related factor 2 (Nrf2), a key transcriptional regulator for antioxidant response element (ARE) mediates induction of cellular antioxidants and detoxifying proteins. We have preliminary data to support that curcumin and flaxseed lignans, safe, naturally occurring, plant-derived, pleiotropic compounds with known antioxidant, anti-inflammatory and anticarcinogenic characteristics, activate the Nrf2/ARE pathway and mediate transcription of antioxidant and cytoprotective genes. We hypothesize that coordinate induction of Nrf2/ARE regulated antioxidant genes may be a novel therapeutic strategy to alleviate radiation pneumonopathy. This study will determine using novel molecular methodologies, two potential mechanisms by which these agents activate Nrf2: kinase-mediated phosphorylation and increased Nrf2 protein stability (Specific Aim 1) and will explore the potential pulmonary radioprotective efficacy of these agents in a well-established murine model of radiation lung injury using dietary formulations of curcumin and flaxseed in Nrf2 trangenic animals and wild type controls (Specific Aim 2). The findings of this work regarding mechanism of action and their usefulness in lung radioprotection in experimental animals and the knowledge that these phytochemicals can be safely administered to humans will enable the design of future clinical trials in the context of cancer treatment.
描述(由申请人提供):胸部放射治疗的有效性受到肺组织对根除恶性细胞所需辐射剂量的敏感性的极大限制。临床上显著的放射性肺损伤,如肺炎样炎症和晚期纤维化,发生在高达30%的肺癌放射治疗患者和约10-15%的其他胸部肿瘤患者中。然而,保护“正常”肺实质免受不可接受的辐射损伤的需要损害了递送杀肿瘤放射治疗剂量的能力。活性氧物质(ROS),如电离辐射大量诱导的那些被认为是纤维化肺疾病的发病机制显着贡献。然而,从氧化性组织损伤到晚期放射性纤维化的分子途径尚不清楚,目前还没有可用的自由基清除剂来提供可接受水平的肺放射保护而没有严重的副作用。我们和其他人已经表明,抗氧化酶治疗可减轻放射性纤维化肺病。最近发现的NF-E2相关因子2(Nrf 2)是抗氧化反应元件(ARE)的关键转录调节因子,介导细胞抗氧化剂和解毒蛋白的诱导。我们有初步数据支持姜黄素和亚麻籽木脂素,安全,天然存在,植物来源,多效性化合物与已知的抗氧化剂,抗炎和抗癌特性,激活Nrf 2/ARE途径和介导的抗氧化剂和细胞保护基因的转录。我们推测,协同诱导Nrf 2/ARE调控的抗氧化基因可能是减轻放射性肺炎的一种新的治疗策略。这项研究将使用新的分子方法来确定这些药物激活Nrf 2的两种潜在机制:激酶介导的磷酸化和增加的Nrf 2蛋白稳定性(特定目的1),并将在Nrf 2转基因动物和野生型对照中使用姜黄素和亚麻籽的膳食制剂在良好建立的放射性肺损伤小鼠模型中探索这些药剂的潜在肺放射保护功效(具体目标2)。这项工作的结果有关的作用机制和它们在肺辐射保护实验动物和知识,这些植物化学物质可以安全地管理给人类的有用性,将使未来的临床试验的癌症治疗的背景下的设计。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Melpo Christofidou-Solomidou其他文献

Melpo Christofidou-Solomidou的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Melpo Christofidou-Solomidou', 18)}}的其他基金

NOVEL SYNTHETIC SDG TO TREAT TRAUMA-INDUCED INFLAMMATION
治疗创伤引起的炎症的新型合成 SDG
  • 批准号:
    8984869
  • 财政年份:
    2015
  • 资助金额:
    $ 17.24万
  • 项目类别:
NOVEL SYNTHETIC SDG TO TREAT TRAUMA-INDUCED INFLAMMATION
治疗创伤引起的炎症的新型合成 SDG
  • 批准号:
    8824322
  • 财政年份:
    2015
  • 资助金额:
    $ 17.24万
  • 项目类别:
Piperlongumine as a Novel Radiosensitizer for Lung Cancer
Piperlongumine 作为肺癌的新型放射增敏剂
  • 批准号:
    9017962
  • 财政年份:
    2015
  • 资助金额:
    $ 17.24万
  • 项目类别:
Mesothelioma inhibition by secoisolariciresinol diglucoside (SDG)
开环异落叶松树脂醇二葡萄糖苷 (SDG) 抑制间皮瘤
  • 批准号:
    8695307
  • 财政年份:
    2013
  • 资助金额:
    $ 17.24万
  • 项目类别:
Mesothelioma inhibition by secoisolariciresinol diglucoside (SDG)
开环异落叶松树脂醇二葡萄糖苷 (SDG) 抑制间皮瘤
  • 批准号:
    8598613
  • 财政年份:
    2013
  • 资助金额:
    $ 17.24万
  • 项目类别:
Mitigation of Radiation Pneumonopathy By Lignan Action
通过木酚素作用缓解放射性肺炎
  • 批准号:
    7586002
  • 财政年份:
    2010
  • 资助金额:
    $ 17.24万
  • 项目类别:
Secoisolariciresinol Diglucoside (SDB) Protection in Radiation Pheumonopathy
开环异落叶松树脂醇二葡萄糖苷 (SDB) 对放射性肺病的保护作用
  • 批准号:
    8501743
  • 财政年份:
    2008
  • 资助金额:
    $ 17.24万
  • 项目类别:
Secoisolariciresinol Diglucoside (SDB) Protection in Radiation Pheumonopathy
开环异落叶松树脂醇二葡萄糖苷 (SDB) 对放射性肺病的保护作用
  • 批准号:
    7895840
  • 财政年份:
    2008
  • 资助金额:
    $ 17.24万
  • 项目类别:
Secoisolariciresinol Diglucoside (SDB) Protection in Radiation Pheumonopathy
开环异落叶松树脂醇二葡萄糖苷 (SDB) 对放射性肺病的保护作用
  • 批准号:
    7693716
  • 财政年份:
    2008
  • 资助金额:
    $ 17.24万
  • 项目类别:
Secoisolariciresinol Diglucoside (SDB) Protection in Radiation Pheumonopathy
开环异落叶松树脂醇二葡萄糖苷 (SDB) 对放射性肺病的保护作用
  • 批准号:
    8103929
  • 财政年份:
    2008
  • 资助金额:
    $ 17.24万
  • 项目类别:

相似海外基金

Enhancing gamete cryoprotective properties of graphene oxide by dual functionalization with antioxidants and non-penetrating cryoprotectant molecules
通过抗氧化剂和非渗透性冷冻保护剂分子的双重功能化增强氧化石墨烯的配子冷冻保护特性
  • 批准号:
    24K18002
  • 财政年份:
    2024
  • 资助金额:
    $ 17.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Bilirubin Catabolism induces Plasminogen-Activator Inhibitor 1 (PAI-1) worsening Metabolic Dysfunction
胆红素分解代谢诱导纤溶酶原激活剂抑制剂 1 (PAI-1) 恶化代谢功能障碍
  • 批准号:
    10750132
  • 财政年份:
    2024
  • 资助金额:
    $ 17.24万
  • 项目类别:
Role of Creatine Metabolism in Necrotizing Enterocolitis
肌酸代谢在坏死性小肠结肠炎中的作用
  • 批准号:
    10724729
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
Redox stress resilience in aging skeletal muscle
衰老骨骼肌的氧化还原应激恢复能力
  • 批准号:
    10722970
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
Investigating Parkin-mediated Neuronal Energy Maintenance in Methamphetamine Use Disorder
研究甲基苯丙胺使用障碍中 Parkin 介导的神经元能量维持
  • 批准号:
    10736697
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
Optimal Oxygenation in Neonatal Lung Injury
新生儿肺损伤的最佳氧合
  • 批准号:
    10734639
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
Influence of Particulate Matter on Fetal Mitochondrial Programming
颗粒物对胎儿线粒体编程的影响
  • 批准号:
    10734403
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
Transcriptional Activation of p62 by the master antioxidant NRF2 in EBV latency
EBV潜伏期主要抗氧化剂NRF2对p62的转录激活
  • 批准号:
    10726975
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
Developing trimester-specific placenta organ-on-chips to model healthy and oxidative stress and inflammation-associated pathologies
开发妊娠期特异性胎盘器官芯片来模拟健康和氧化应激以及炎症相关的病理学
  • 批准号:
    10732666
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
Semiconductor Biomaterials to Speed Bone Healing: A Bioengineering-Driven Approach
半导体生物材料加速骨骼愈合:生物工程驱动的方法
  • 批准号:
    10587508
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了